|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,475 |
$2,513,981.25 |
7.27% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
10,477 |
$2,414,110.34 |
6.98% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
21,021 |
$2,384,832.45 |
6.90% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
41,733 |
$2,353,323.87 |
6.80% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
11,216 |
$2,338,536.00 |
6.76% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
87,169 |
$1,514,125.53 |
4.38% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
6,784 |
$1,387,531.52 |
4.01% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
47,068 |
$1,221,885.28 |
3.53% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,665 |
$1,198,600.20 |
3.47% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,620 |
$1,187,017.20 |
3.43% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
8,738 |
$1,162,590.90 |
3.36% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
3,353 |
$1,128,116.85 |
3.26% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,920 |
$1,112,716.80 |
3.22% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
5,678 |
$1,058,095.30 |
3.06% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,943 |
$916,077.19 |
2.65% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
8,062 |
$796,686.84 |
2.30% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
9,927 |
$737,973.18 |
2.13% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
4,308 |
$624,660.00 |
1.81% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
12,111 |
$621,173.19 |
1.80% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
3,099 |
$499,930.68 |
1.45% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
6,420 |
$471,613.20 |
1.36% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
1,019 |
$431,811.44 |
1.25% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,896 |
$412,896.88 |
1.19% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,505 |
$407,939.25 |
1.18% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
7,443 |
$398,572.65 |
1.15% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
9,873 |
$384,158.43 |
1.11% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
4,162 |
$317,602.22 |
0.92% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
12,871 |
$280,587.80 |
0.81% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
6,008 |
$267,656.40 |
0.77% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,948 |
$253,682.20 |
0.73% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
7,756 |
$241,676.96 |
0.70% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
3,076 |
$239,558.88 |
0.69% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
8,787 |
$219,675.00 |
0.64% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,940 |
$211,770.40 |
0.61% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,815 |
$207,497.85 |
0.60% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
649 |
$202,864.42 |
0.59% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
902 |
$199,531.42 |
0.58% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,944 |
$201,942.72 |
0.58% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
15,297 |
$189,529.83 |
0.55% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,906 |
$187,683.82 |
0.54% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
6,185 |
$180,725.70 |
0.52% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
2,205 |
$171,108.00 |
0.49% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,960 |
$167,756.40 |
0.49% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
3,341 |
$168,453.22 |
0.49% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
3,271 |
$167,998.56 |
0.49% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
7,765 |
$163,608.55 |
0.47% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
7,288 |
$161,647.84 |
0.47% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
538 |
$156,816.24 |
0.45% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,371 |
$153,308.86 |
0.44% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
6,637 |
$143,956.53 |
0.42% |
| US Dollar |
$USD |
|
Other |
49,444 |
$49,444.19 |
0.14% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|